CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
RhoVac is developing RV001, a therapeutic vaccine targeting early-stage metastatic prostate cancer by reprogramming the patient's T cells. This innovative approach aims to prevent cancer relapses and offers a promising alternative to current treatments that focus on later stages of the disease.
Prostate cancer is the most commonly diagnosed cancer among men, with an anticipated 1.7M new cases and 499,000 deaths by 2030 worldwide.
Although, most cancer therapies available focus on treatment of the primary tumor, the leading cause of cancer morbidity and mortality is metastasis.
Today’s current treatments for metastatic prostate cancer focus on later stage of the cancer progression, when the signs of metastasis spread are already observed; and modestly prolong the patient’s survival and…
RHOVAC APS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
